Exenatide showed a beneficial effect on cardiovascular outcomes, albeit with borderline significance (Holman et al., 2017 ), whereas a separate trial of lixisenatide found no evidence of benefit (Pfeffer et al., 2015 ).
← all excerpts
Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.
1
—
—